Drug Profile
HW 4102
Alternative Names: HW-4102Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Nanjing Huawe Medicine Technology Development
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in China
- 29 Jul 2016 Preclinical trials in Cancer in China (unspecified route)